悍高集团今日下跌8.48%，全天换手率23.17%，成交额5.23亿元，振幅5.68%。龙虎榜数据显示，机构净 卖出2585.66万元，深股通净卖出1224.77万元，营业部席位合计净买入1218.72万元。 深交所公开信息显示，当日该股因日换手率达23.17%上榜，机构专用席位净卖出2585.66万元，深股通 净卖出1224.77万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.46亿元，其中，买入成交额为6017.68 万元，卖出成交额为8609.39万元，合计净卖出2591.71万元。 （文章来源：证券时报网） 近半年该股累计上榜龙虎榜8次，上榜次日股价平均跌2.74%，上榜后5日平均跌8.24%。 资金流向方面，今日该股主力资金净流出1869.93万元，其中，特大单净流出357.25万元，大单资金净流 出1512.68万元。近5日主力资金净流出1116.56万元。（数据宝） 悍高集团9月26日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 深股通专用 | 3446.98 | ...

Core Viewpoint - The stock of Guojijinggong experienced a significant decline, hitting the daily limit down, with a trading volume of 1.453 billion yuan and a turnover rate of 9.42% [2] Group 1: Trading Activity - The stock's price fell by 8.46%, leading to its inclusion on the Shenzhen Stock Exchange's watch list for price deviation [2] - Institutional investors net sold 4.4014 million yuan, while the Shenzhen Stock Connect saw a net purchase of 89.848 million yuan [2] - The top five trading departments accounted for a total transaction volume of 625 million yuan, with net selling of 181 million yuan [2] Group 2: Institutional Participation - Three institutional special seats were involved in trading, with a total buying amount of 48.9664 million yuan and selling amount of 53.3678 million yuan, resulting in a net sell of 4.4014 million yuan [2] - The Shenzhen Stock Connect was the largest buying department with a purchase of 161.543 million yuan and a selling amount of 70.8063 million yuan, leading to a net purchase of 89.848 million yuan [2] Group 3: Recent Performance - Over the past six months, the stock has appeared on the watch list six times, with an average price increase of 3.72% the day after being listed and an average increase of 8.12% in the following five days [3] - The stock saw a net outflow of 377 million yuan in main funds today, with large orders contributing to a net outflow of 190 million yuan and 187 million yuan respectively [3]

人民财讯9月26日电，富煌钢构（002743）9月26日公告，公司9月26日收到中国证监会对公司送达的 《立案告知书》，公司因涉嫌信息披露违法违规，证监会决定对公司进行立案。目前公司各项经营活动 和业务均正常开展。 ...

同时，公司拟终止"新建微型锂离子电池及精密零部件生产项目"，并将剩余募集资金永久补充流动资 金，因现有的产能在一定时间段内已能够满足客户开发和生产需要。 人民财讯9月26日电，万祥科技（301180）9月26日公告，目前公司华南生产基地情况较披露预案时发生 较大变化，考虑后续资金成本以及结合自身实际情况，公司决定终止向不特定对象发行可转换公司债券 事项。 ...

Core Viewpoint - Anbang Guard (603373) officially joined the "Zhejiang Province Overseas Comprehensive Service Partner Program" at the Fourth Global Digital Trade Expo, marking a significant step in supporting Zhejiang enterprises in their international ventures [1] Group 1 - The company's participation in the program reflects its proactive approach to integrate into the "High-level Open Strong Province" initiative [1] - This move emphasizes the company's commitment to its core responsibility in security services [1] - Joining the program is a strategic measure to enhance the safety and support for Zhejiang enterprises going global [1]

在血液技术产业上，海尔生物主要展示的是今年刚刚上市的一次性使用去白细胞塑料血袋，该产品集成 了献血前采样、主管易折二通及针刺保护装置，在提升操作便捷性的同时给予医护人员更完善的防护， 构成了海尔生物搭建血液智能化管理全流程生态的关键一环。 海尔生物表示，今年上半年，公司通过加大AI技术底座建设，实现了对"四横四纵"开放创新体系的升 级。该体系融合了AI、自动化、智能化和材料等4大通用技术平台，以及制冷、环境控制、分选分离、 生物应用等4大垂直技术平台，响应不同细分市场需求。上半年内，公司已实现10类产品方案首发或首 创，进一步强化行业引领者的地位。 9月26日，第92届中国国际医疗器械(秋季)博览会，即业内俗称的"秋季CMEF"，在广交会展馆开幕。本 届秋季CMEF吸引了全球近20个国家的近3000家企业携数万件产品亮相，据测算有超12万名专业观众到 场。 本届秋季CMEF上，海尔生物(688139)携旗下四大产业(实验室解决方案、智慧用药、血液技术、低温存 储)20余款创新产品和解决方案亮相，覆盖样本存储、智慧耗材、药品存储、生物培养、离心分离、血 液采集及存储等多个生命科学和医疗创新应用场景。 其中，在低 ...

人民财讯9月26日电，合合信息(688615)9月26日公告，东方富海及东方富海二号合计持有公司1043.34万 股，占7.45%。二者计划通过集中竞价或大宗交易方式，合计减持公司股份不超过420万股，比例不超 过3%。 转自：证券时报 ...

Group 1 - The core theme of the second R&D Technology Week held by Heertai is "Technology Co-creation, Ecological Win-win," showcasing four self-developed core technology platforms including HMI solutions and AI algorithm platforms [1] - Heertai's operating performance has shown significant breakthroughs, with a reported revenue of 5.446 billion yuan in the first half of the year, representing a year-on-year growth of 19.21%, laying a solid foundation for annual development [1] - The company has established a joint venture with Leju Intelligent and Dongfang Precision Engineering, focusing on the field of embodied intelligent robots, with Heertai holding a 60% stake, which will drive strategic development and industrial layout [1] Group 2 - Heertai has demonstrated forward-looking strategic vision in its investment layout, with its subsidiary Moer Thread's IPO application passing the listing review, marking a significant breakthrough in the AI and GPU sectors [2] - Moer Thread is a leading domestic GPU chip design company, focusing on high-performance computing and graphics rendering technology, with broad application prospects in AI, the metaverse, and autonomous driving [2] - The successful listing of Moer Thread will enhance Heertai's investment returns and asset value, increasing the overall valuation potential of the company [2]

Core Viewpoint - Jiangzhong Pharmaceutical (600750) announced the acquisition of 70% equity in Anhui Jingcheng Huyao Pharmaceutical Co., Ltd. for a price not exceeding 70.78393 million yuan, aiming to enhance its OTC product matrix with traditional Chinese medicine products [1] Group 1: Acquisition Details - The acquisition will allow Jiangzhong Pharmaceutical to supplement its product offerings in the traditional Chinese medicine sector, particularly in the health supplement category [1] - Anhui Jingcheng Huyao, established in November 2013 with a registered capital of 51 million yuan, focuses on the R&D, production, and sales of traditional Chinese medicine [1] - The core products of Jingcheng Huyao include Liuwei Dihuang Oral Liquid, Nao Li Jing Syrup, and Nao Li Jing Capsules [1] Group 2: Company Background - Jingcheng Huyao was previously known as Bengbu Traditional Chinese Medicine Factory, founded in 1968, and was fully acquired by Peitian Group in 2015 [1] - The company was listed on the Specialized and New Board of Anhui Stock Custody Center in October 2021 [1] Group 3: Operational Challenges - Peitian Group, the current owner of Jingcheng Huyao, has faced operational difficulties due to poor management, market changes, and heavy debt burdens, leading to a debt crisis in 2018 [3] - The company underwent a restructuring process initiated by the government and asset management companies to address its financial issues [3] - As part of the restructuring plan, the court approved a merger and restructuring plan for Peitian Group and its subsidiaries, including Jingcheng Huyao, in September 2024 [3]

今年8月14日晚间，京东健康发布2025年中期业绩公告显示，上半年实现总收入为353亿元，同比增长 24.5%；非国际财务报告准则指标下（Non-IFRS）净利润达35.7亿元，同比增长35%。截至2025年6月30 日，京东健康过去12个月的年度活跃用户数量突破2亿；京东互联网医院日均问诊单量超过50万。 在用药指导方面，京东药师可以讲解药品的用法用量、使用禁忌以及出现不良反应时的应对措施；针对 慢病患者，京东药师会为他们建立健康档案，制定个性化用药计划，并进行生活方式干预和定期随访， 必要时还会协调其他优质医疗资源，提升慢病控制效果；京东药师还通过直播、短视频、图文海报等形 式，普及药学知识，提升用户安全用药意识，从源头降低用药风险。 "药师绝不是药品销售员，而是健康的守护者"，京东健康相关负责人表示，《京东药师宣言》不仅是承 诺，更是京东药师的行为准绳。未来，京东药师将持续以专业能力为基础，以用户需求为根本，让用户 的每一次购药都安心，每一次用药都科学合理。 9月25日是第17个"世界药师节"，京东健康最近联合新华网（603888）发布《京东药师宣言》，向行业 顽疾—药品推销"宣战"。京东健康表示，旗下 ...